Maдопар

Levodopa and Benserazide, the active ingredients in Maдопар, are antiparkinson agents presented as an oral tablet for oral use. They treat Parkinson's disease and related Parkinsonian syndromes in adults.

GNH USA supplies Maдопар as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar is an antiparkinson agent used to manage motor symptoms in dopamine‑deficient disorders.

Parkinson's disease: improves bradykinesia, rigidity, and tremor. Parkinsonian syndrome: provides symptomatic relief of dopamine deficiency. Levodopa‑responsive Parkinsonism: enhances daily functioning by increasing central dopamine levels.

Common Side Effects: - Nausea or vomiting. - Dizziness or light‑headedness. - Headache. - Dry mouth.

Serious or Rare Side Effects: - Dyskinesia (involuntary movements). - Psychiatric disturbances such as hallucinations or confusion. - Severe hypotension or orthostatic collapse. - Neuroleptic malignant syndrome. - Allergic reactions including skin rash or anaphylaxis.

Before initiating therapy, consider the following precautions: - Dose titration: start low and adjust under medical supervision. - Monitor for dyskinesia: watch for involuntary movements during treatment. - Assess cardiovascular status: risk of orthostatic hypotension. - Avoid in patients with narrow‑angle glaucoma. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Madopar may interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may reduce antiparkinson efficacy. - Antihypertensive agents: additive hypotensive effect. - Iron supplements: decrease levodopa absorption. - High‑protein meals: reduce drug bioavailability.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may increase levodopa plasma levels. - Serotonergic agents: risk of serotonin syndrome. - Carbidopa or other decarboxylase inhibitors: may enhance therapeutic effect.